6
RAJABZADEH ET AL.
3.3.1
entry 1)
|
1‐(4‐Methoxyphenyl)‐1H–benzo[d]imidazole (Table 2,
(d, 1H, J = 1.2 Hz), 7.75 (d, 1H, J = 2.4 Hz). 13C NMR
(75 MHz, CDCl3, δ, ppm): 55.58, 107.17, 114.51, 120.92,
126.83, 134.04, 140.63, 158.24. MS (EI): m/z (%) 174 [M+].
1H NMR (DMSO, 300 MHz, δ, ppm): 3.85 (s, 3H), 7.17 (d,
2H, J = 8.7 Hz), 7.27–7.79 (m, 4H), 7.59 (d, 2H, J = 9 Hz),
8.47 (s, 1H). 13C NMR (75 MHz, DMSO, δ, ppm): 56.00,
110.92, 115.60, 120.31, 122.69, 123.75, 125.90, 129.26,
134.07, 143.98, 159.16. MS (EI): m/z (%) 224 [M+].
3.3.8
entry 11)
| 1‐(2‐Methyl‐4‐nitrophenyl)‐1H–pyrazole (Table 2,
1H NMR (CDCl3, 300 MHz, δ, ppm): 2.46 (s, 3H), 6.53 (t,
1H), 7.54 (d, 1H, J = 8.7 Hz), 7.73 (d, 1H, J = 2.4 Hz),
7.79 (d, 1H, J = 1.5 Hz), 8.14 (dd, 1H, J1 = 8.7 Hz,
J2 = 2.4 Hz), 8.22 (d, 1H, J = 2.4 Hz). 13C NMR
(75 MHz, CDCl3, δ, ppm): 19.10, 107.58, 122.02, 126.27,
126.82, 130.50, 134.35, 141.56, 144.67, 146.61.MS (EI):
m/z (%) 203 [M+].
3.3.2
(Table 2, entry 3)
| 1‐(2‐Methyl‐4‐nitrophenyl)‐1H–benzo[d]imidazole
1H NMR (CDCl3, 300 MHz, δ, ppm): 2.30 (s, 3H), 7.16 (dd,
1H, J1 = 6.6 Hz, J2 = 1.5 Hz), 7.34–7.43 (m, 2H), 7.55 (d,
1H, J = 8.7 Hz), 7.94 (d.d, 1H, J1 = 6 Hz, J2 = 2.1 Hz),
8.21 (s, 1H), 8.27 (d.d, 1H, J1 = 8.4 Hz, J2 = 2.4 Hz), 8.36
(d, 1H, J = 2.1 Hz). 13C NMR (75 MHz, CDCl3, δ, ppm):
18.17, 110.16, 120.90, 122.54, 123.23, 124.25, 126.78,
128.51, 134.04, 137.10, 140.34, 142.11, 143.48, 147.71.
MS (EI): m/z (%) 253 [M+].
3.3.9
| 1‐(4‐Bromophenyl)‐1H–pyrazole (Table 2, entry 12)
1H NMR (CDCl3, 300 MHz, δ, ppm): 6.49 (t, 1H), 7.59 (AB
q, 4H), 7.74 (d, 1H, J = 2.4 Hz), 7.90 (d, 1H, J = 2.4 Hz). 13C
NMR (75 MHz, CDCl3, δ, ppm): 108.06, 119.63, 120.58,
126.65, 132.47, 138.41, 141.42. MS (EI): m/z (%) 221 [M+].
3.3.3
entry 4)
| 1‐(6‐Iodopyridin‐3‐yl)‐1H–benzo[d]imidazole (Table 2,
1H NMR (CDCl3, 300 MHz, δ, ppm): 7.34–7.39 (m, 2H),
7.76 (d, 1H, J = 6.6 Hz), 7.96 (d, 1H, J = 8.7 Hz), 8.26–
8.33 (m, 1H), 8.76 (d, 1H, J = 2.4 Hz), 8.85 (d, 1H,
J = 1.8 Hz), 8.98 (s, 1H). 13C NMR (75 MHz, CDCl3, δ,
ppm): 113.51, 115.72, 119.36, 123.52, 131.14, 141.39,
143.63, 146.69, 148.22, 148.87, 153.84. MS (EI): m/z (%)
320 [M+].
3.3.10
entry 14)
| 1‐(4‐Methoxyphenyl)‐1H‐1,2,4‐triazole (Table 2,
1H NMR (CDCl3, 300 MHz, δ, ppm): 3.79 (s, 3H), 6.93 (d,
2H, J = 8.7 Hz), 7.50 (d, 2H, J = 8.7 Hz), 8.01 (s, 1H),
8.38 (s, 1H). 13C NMR (75 MHz, CDCl3, δ, ppm): 55.64,
114.83, 121.99, 130.47, 152.41, 159.47. MS (EI): m/z (%)
175 [M+].
3.3.4
(Table 2, entry 5)
| 1‐(4‐Methoxyphenyl)‐2‐methyl‐1H‐benzo[d]imidazole
3.3.11
| 1‐(4‐Bromophenyl)‐1H‐1,2,4‐triazole (Table 2, entry 16)
1H NMR (CDCl3, 300 MHz, δ, ppm): 7.59 (q, 4H). 8.10 (s,
1H), 8.55 (s, 1H). 13C NMR (75 MHz, CDCl3, δ, ppm):
121.43, 132.86, 135.98, 138.83, 140.80, 152.76. MS (EI):
m/z (%) 223 [M+].
1H NMR (DMSO, 300 MHz, δ, ppm): 2.51 (s, 3H), 3.93 (s,
3H), 7.09–7.31 (m, 7H), 7.65 (d, 1H, J = 7.2 Hz). 13C
NMR (75 MHz, DMSO, δ, ppm): 14.33, 55.63, 109.92,
115.05, 118.92, 122.35, 128.34, 128.66, 136.84, 142.50,
151.95, 159.75. MS (EI): m/z (%) 238 [M+].
3.3.12
(Table 2, entry 17)
|
1‐(4‐Methoxyphenyl)‐1H–benzo[d] [1–3]triazole
3.3.5
(Table 2, entry 6)
| 1‐(4‐Methoxyphenyl)‐5‐nitro‐1H‐benzo[d]imidazole
1H NMR (CDCl3, 300 MHz, δ, ppm): 3.93 (s, 3H), 7.14
(d, 2H, J = 8.4 Hz), 7.45 (t, 1H), 7.55 (t, 1H), 7.6 (d, 1H,
J = 8.1 Hz), 8.16 (d, 1H, J = 8.1 Hz). 13C NMR (75 MHz,
CDCl3, δ, ppm): 55.68, 110.26, 114.98, 120.22, 124.43,
128.03, 130.00, 132.65, 146.32, 159.84. MS (EI): m/z (%)
225 [M+].
1H NMR (CDCl3, 300 MHz, δ, ppm): 3.88 (s, 3H), 7.23–8.87
(m, 8H). MS (EI): m/z (%) 269 [M+].
3.3.6
(Table 2, entry 7)
| 5‐Nitro‐1‐(4‐nitrophenyl)‐1H–benzo[d]imidazole
1H NMR (CDCl3, 300 MHz, δ, ppm): 7.68 (1H, d, J = 9 Hz),
7.79 (d, 2H, J = 9 Hz), 8.37 (dd, 1H, J1 = 9 Hz, J2 = 2.1 Hz),
8.38 (s, 1H), 8.56 (d, 2H, J = 9 Hz), 8.86 (d, 1H, J = 2.1 Hz).
13C NMR (75 MHz, CDCl3, δ, ppm): 110.41, 117.86,
120.24, 124.42, 126.13, 136.89, 140.46, 143.91, 144.80,
147.44. MS (EI): m/z (%) 284 [M+].
4
| CONCLUSIONS
In summary, we have reported an efficient procedure for the
synthesis of Cu nanorods using a polydentate ligand. The
application of the Fe3O4@SiO2/EP.EN.EG@Cu catalyst in
N‐arylation of nitrogen‐containing heterocycles has been
examined, and high yields of the products were achieved. In
addition, the catalyst could be easily recovered and reused
for at least five cycles.
3.3.7
| 1‐(4‐Methoxyphenyl)‐1H–pyrazole (Table 2, entry 9)
1H NMR (CDCl3, 300 MHz, δ, ppm): 3.77 (s, 3H), 6.36 (t,
1H), 6.89 (d, 2H, J = 9 Hz), 7.51 (d, 2H, J = 9 Hz), 7.62